DME Capital Management’s Gain Therapeutics GANX Stock Holding History

DME Capital Management’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.15M	Hold	566,130	–	–	0.03%	45
2026 Q1	$1.1M	Hold	566,130	–	–	0.03%	43
2025 Q4	$1.82M	Hold	566,130	–	–	0.06%	37
2025 Q3	$1M	Hold	566,130	–	–	0.04%	34
2025 Q2	$1.02M	Hold	566,130	–	–	0.04%	31
2025 Q1	$1.08M	Hold	566,130	–	–	0.05%	30
2024 Q4	$1.22M	Hold	566,130	–	–	0.06%	33
2024 Q3	$1.01M	Hold	566,130	–	–	0.04%	34
2024 Q2	$725K	Hold	566,130	–	–	0.04%	36
2024 Q1	$2.13M	Buy	+566,130	New	+$2.35M	0.1%	34

Other funds holding GANX

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PCM

Potomac Capital Management New York $147M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

DME Capital Management's GANX Position: Q2 2026 in Review

DME Capital Management held its Gain Therapeutics (GANX) position steady in Q2 2026 at 566,130 shares worth $1.15M. The position accounts for 0.03% of the portfolio, ranked #45.

DME Capital Management first reported a position in GANX in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.13M in Q1 2024. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

DME Capital Management held 566,130 shares of Gain Therapeutics worth $1.15M as of Q2 2026.
DME Capital Management left its Gain Therapeutics share count unchanged in Q2 2026.
Gain Therapeutics made up 0.03% of DME Capital Management's portfolio in Q2 2026, its #45 holding.
DME Capital Management first reported a position in Gain Therapeutics in Q1 2024 and has held it in 10 quarters since.
DME Capital Management's Gain Therapeutics position peaked at $2.13M in Q1 2024.
50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on DME Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.